tetano
Editor, Senior Moderator
Nat Commun
. 2021 Jul 26;12(1):4598.
doi: 10.1038/s41467-021-24909-9.
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Satoshi Ikegame[SUP] 1 [/SUP], Mohammed N A Siddiquey[SUP] #[/SUP][SUP] 2 [/SUP], Chuan-Tien Hung[SUP] #[/SUP][SUP] 1 [/SUP], Griffin Haas[SUP] 1 [/SUP], Luca Brambilla[SUP] 1 [/SUP], Kasopefoluwa Y Oguntuyo[SUP] 1 [/SUP], Shreyas Kowdle[SUP] 1 [/SUP], Hsin-Ping Chiu[SUP] 1 [/SUP], Christian S Stevens[SUP] 1 [/SUP], Ariel Esteban Vilardo[SUP] 3 [/SUP], Alexis Edelstein[SUP] 3 [/SUP], Claudia Perandones[SUP] 3 [/SUP], Jeremy P Kamil[SUP] 2 [/SUP], Benhur Lee[SUP] 4 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 180 million people since its identification as the cause of the current COVID-19 pandemic. The rapid pace of vaccine development has resulted in multiple vaccines already in use worldwide. The contemporaneous emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse geographic locales underscores the need to monitor the efficacy of vaccines being administered globally. All WHO designated VOC carry spike (S) polymorphisms thought to enable escape from neutralizing antibodies. Here, we characterize the neutralizing activity of post-Sputnik V vaccination sera against the ensemble of S mutations present in alpha (B.1.1.7) and beta (B.1.351) VOC. Using de novo generated replication-competent vesicular stomatitis virus expressing various SARS-CoV-2-S in place of VSV-G (rcVSV-CoV2-S), coupled with a clonal 293T-ACE2 + TMPRSS2 + cell line optimized for highly efficient S-mediated infection, we determine that only 1 out of 12 post-vaccination serum samples shows effective neutralization (IC[SUB]90[/SUB]) of rcVSV-CoV2-S: B.1.351 at full serum strength. The same set of sera efficiently neutralize S from B.1.1.7 and exhibit only moderately reduced activity against S carrying the E484K substitution alone. Taken together, our data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines.
. 2021 Jul 26;12(1):4598.
doi: 10.1038/s41467-021-24909-9.
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Satoshi Ikegame[SUP] 1 [/SUP], Mohammed N A Siddiquey[SUP] #[/SUP][SUP] 2 [/SUP], Chuan-Tien Hung[SUP] #[/SUP][SUP] 1 [/SUP], Griffin Haas[SUP] 1 [/SUP], Luca Brambilla[SUP] 1 [/SUP], Kasopefoluwa Y Oguntuyo[SUP] 1 [/SUP], Shreyas Kowdle[SUP] 1 [/SUP], Hsin-Ping Chiu[SUP] 1 [/SUP], Christian S Stevens[SUP] 1 [/SUP], Ariel Esteban Vilardo[SUP] 3 [/SUP], Alexis Edelstein[SUP] 3 [/SUP], Claudia Perandones[SUP] 3 [/SUP], Jeremy P Kamil[SUP] 2 [/SUP], Benhur Lee[SUP] 4 [/SUP]
Affiliations
- PMID: 34312390
- DOI: 10.1038/s41467-021-24909-9
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 180 million people since its identification as the cause of the current COVID-19 pandemic. The rapid pace of vaccine development has resulted in multiple vaccines already in use worldwide. The contemporaneous emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse geographic locales underscores the need to monitor the efficacy of vaccines being administered globally. All WHO designated VOC carry spike (S) polymorphisms thought to enable escape from neutralizing antibodies. Here, we characterize the neutralizing activity of post-Sputnik V vaccination sera against the ensemble of S mutations present in alpha (B.1.1.7) and beta (B.1.351) VOC. Using de novo generated replication-competent vesicular stomatitis virus expressing various SARS-CoV-2-S in place of VSV-G (rcVSV-CoV2-S), coupled with a clonal 293T-ACE2 + TMPRSS2 + cell line optimized for highly efficient S-mediated infection, we determine that only 1 out of 12 post-vaccination serum samples shows effective neutralization (IC[SUB]90[/SUB]) of rcVSV-CoV2-S: B.1.351 at full serum strength. The same set of sera efficiently neutralize S from B.1.1.7 and exhibit only moderately reduced activity against S carrying the E484K substitution alone. Taken together, our data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines.